Early Access

10-QPeriod: Q1 FY2020

INTUITIVE SURGICAL INC Quarterly Report for Q1 Ended Mar 31, 2020

Filed April 17, 2020For Securities:ISRG

Summary

Intuitive Surgical Inc. (ISRG) reported its first quarter 2020 results, a period significantly impacted by the emerging COVID-19 pandemic. Despite early growth in China and other regions in January and February, the latter half of March saw a sharp decline in procedures, particularly in the U.S., due to widespread deferral of elective surgeries. Total revenue saw a 13% increase year-over-year to $1.1 billion, driven by growth in instruments, accessories, systems, and services. However, gross profit margin slightly decreased to 67.1% from 68.8% in the prior year, impacted by increased costs. The company maintains a strong liquidity position with $5.9 billion in cash, cash equivalents, and investments as of March 31, 2020. The company's outlook for the second quarter and beyond is highly uncertain due to the pandemic's ongoing effects. Procedure volume and system placements are expected to decline significantly. Intuitive Surgical has withdrawn its full-year 2020 guidance. While the company has a robust pipeline of new products and a strong installed base, the immediate future will be shaped by the trajectory of the pandemic and its impact on global healthcare systems and economies.

Financial Statements
Beta

Key Highlights

  • 1Total revenue increased by 13% to $1.1 billion for the three months ended March 31, 2020, compared to $974 million in the prior year.
  • 2Da Vinci procedures increased by 10% to approximately 309,000 for the quarter, but saw a significant decline in the latter half of March due to COVID-19.
  • 3U.S. procedures experienced a sharp decline of approximately 65% in the last half of March 2020.
  • 4Instruments and accessories revenue grew 12% to $618 million, and systems revenue increased 14% to $283 million.
  • 5Gross profit as a percentage of revenue decreased slightly to 67.1% from 68.8% year-over-year.
  • 6The company ended the quarter with $5.9 billion in cash, cash equivalents, and investments, indicating strong liquidity.
  • 7Full-year 2020 financial and procedure guidance has been withdrawn due to the uncertainty surrounding the COVID-19 pandemic.

Frequently Asked Questions